NAB-Sure™

Cell-free Neutralizing Antibody Test Kits

Wild Type and Omicron BA.4/5 Test kits available

NAB-Sure SARS-CoV-2 Assay quantifies SARS-CoV-2 virus neutralizing antibodies using qPCR workflows.
NAB-Sure™ SARS CoV-2 Kit is for research use only.

Download Brochure

Quantify neutralizing antibodies with dried blood spot

NAB-Sure SARS CoV-2 Kit simplifies testing from sample collection through result by using real-time PCR systems to produce qualitative and quantitative NAb (titer) measurements. It combines PRNT level accuracy with unparalleled sensitivity to assess small sample volumes including dried blood spot(DBS).

NAB-Sure is a surrogate virus neutralization test. It is a competitive binding assay that measures the ability of antibodies in a sample to block the SARS-CoV-2 Spike Protein from binding to the ACE2 receptor of a human cell. It is a homogenous immunoassay with no separation or wash steps.

Applications

Vaccine Efficacy Testing

Longitudinal Antibody Durability Testing

COVID-19 Serosurveillance

PERFORMANCE

  • Total Test Time: 6 Hours
  • Sample Type: Plasma, Serum, Dried Blood Spot
  • 96 & 384 Well for Manual or Automated Processing

NAB-Sure SARS-CoV-2 Neutralizing Antibody Test Kit Brochure

Download

NAB-SURE SARS-CoV-2 Neutralizing Antibody Test Kit Product Data Sheet

Download
ORDERING

Complete the form on this page or email

info@spear.bio

for ordering information

Learn More About NAB-Sure™

Please fill out the form below

NAB–Sure™ SARS CoV-2 Neutralizing Antibody Test Kit – FAQs

Download FAQ

Spear Bio uses proprietary SPEAR (Successive Proximity Extension Amplification Reaction assay) technology. The assay uses selected oligonucleotides conjugated to antibodies. These oligos can only be extended when they are in proximity, such as when the antibodies have bound to their target. Primer extended products are then detected by standard qPCR.

The NAB-Sure™ SARS-CoV-2 assay is a competitive binding assay that uses Spear Bio technology. It is a surrogate virus neutralization test (sVNT), which measures the ability of antibodies in a sample to block SARS-CoV-2 Spike Protein from binding to the ACE2 receptor protein in solution. The assay is accurate, and highly sensitive and compares favorably with existing neutralizing antibody assays.

Spear Bio uses proprietary SPEAR (Successive Proximity Extension Amplification Reaction assay) technology. The assay uses selected oligonucleotides conjugated to antibodies. These oligos can only be extended when they are in proximity, such as when the antibodies have bound to their target. Primer extended products are then detected by standard qPCR.

Neutralizing antibody assays specifically detect antibodies that block SARS-CoV-2 virus from entering host cells. Existing methods to detect these antibodies include cell-based assays and ELISA-based surrogate virus neutralization assays. Cell-based assays include plaque reduction neutralization test (PRNT), microneutralization assay (MNA), and pseudotyped virus neutralization assay (PVA).

NAB-Sure™ SARS-CoV-2 Assay is specific to neutralizing antibodies as opposed to total antibodies. Present ELISA and EIA immunoassays detect total antibodies against either SARS- CoV-2, the SARS-CoV-2 Spike Protein S1 subunit or the Receptor Binding Domain (RBD) on S1. In addition, NAB-Sure™ SARS-CoV-2 Assay has many advantages over other neutralizing antibody tests. For example, cell-based assays take usually 3-4 days, have high inter-lab variations, and require Bio Safety Level (BSL) 2 – and above – laboratories due to the exposure risk using a live virus. ELISA-based surrogate virus neutralization assays have low sensitivity to detect antibodies from a small sample size.

The Spear Bio’s NAB-Sure™ assay can be used to determine the portion of an individual’s SARS-CoV-2 antibodies that can neutralize the SARS-CoV-2 virus after recent or prior infection or another immune event. Researchers can use the test to further understand the biology and epidemiology of COVID-19 infections. Neutralization assays are also used as surrogate clinical endpoints in vaccine trials.

NAB-Sure™ SARS-CoV-2 Kit is designed to work with standard thermocycler and qPCR systems for 96 and 384 well plates. The assay has been validated with both manual and Integra liquid handling automation systems. Please see the NAB-Sure™ datasheet for more information on specific systems used in development.

The test takes approximately 8 hours if includes processing of dried blood spot (DBS) samples and 6.5 hours if using plasma or serum samples.

This test does NOT detect the SARS-CoV-2 virus. It should not be used to determine infection.

The assay has been validated with DBS, plasma and serum samples.

NAB-Sure™ SARS-CoV-2 Assay is a surrogate virus neutralization assay and results are expressed as NT50, which refers to the sample dilution fold at which 50% of the interaction between S1 protein and ACE2 receptor is inhibited.

Studies performed with 96 subject samples determined that the sensitivity of the assay was 100% (95% CI, 95.35%-100%), and specificity of the assay was 100% (95% CI, 82.35%-100%).

DBS samples need to be properly collected and dried before shipment with desiccant. After receiving DBS samples, they should be stored at -20°C or less until use. Plasma and serum samples need to be properly collected and stored at -20°C or less until use.

Find Us

Address :  100 Tradecenter Dr, Suite 510 , Woburn, MA,01801

Contact Us
(info@spear.bio)